Objectives: The visual acuity prognoses of patients with neuromyelitis optica (NMO) are worse than those with optic neuritis (ON) caused by other diseases. Predicting the prognoses of ON at the time of onset is important for selecting treatments for NMO patients.
Methods: Twenty-three consecutive anti-aquaporin-4 autoantibody-positive NMO patients who presented with ON and had contrast-enhanced optic MRIs in the acute phase of their first ON episode were examined. Optical coherence tomographies (OCTs) were also examined for 22 of them. The visual acuity at the final follow-up, as assessed with the logMAR scale more than three years after ON onset, served as the outcome measure. These variables were also collected from 12 patients with serum anti-myelin oligodendrocyte glycoprotein antibody (anti-MOG-Ab).
Results: The strongest predictor of visual prognosis was the axial ON lesion length in the acute phase (R=0.747, p<0.0001), which was not observed in patients with anti-MOG-Ab. Specifically, the ON lesion length within the intra-orbit and canalicular segments exhibited the strongest correlation with visual prognosis (R=0.783, p<0.0001). The ON onset age was also correlated with visual prognosis (R=0.435, p=0.0338). OCT data in the chronic phase also showed a correlation with visual prognosis, but they were much weaker than the ON lesion length in the acute phase.
Conclusions: The ON lesion length in the acute phase was an important predictor of the visual prognoses of NMO patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jneuroim.2016.02.004 | DOI Listing |
J Integr Neurosci
January 2025
Department of Radiology, Huzhou Central Hospital, The Affiliated Central Hospital of Huzhou University, 313000 Huzhou, Zhejiang, China.
Background: Glioma is the most common malignancy in the central nervous system. Even with optimal therapies, glioblastoma (the most aggressive form of glioma) is incurable, with only 26.5% of patients having a 2-year survival rate.
View Article and Find Full Text PDFPharmaceuticals (Basel)
December 2024
Postgraduate Program in Natural and Synthetic Bioactive Products, Health Sciences Center, Federal University of Paraíba (UFPB), João Pessoa CEP 58051-970, PB, Brazil.
Background: (-)-Fenchone is a bicyclic monoterpene present in the plant species Mill, L. (tuja), and (lavender). These plants have therapeutic value in the treatment of intestinal disorders.
View Article and Find Full Text PDFJ Clin Med
January 2025
Department of Vascular and Endovascular Surgery, Rhein Main Vascular Center, Asklepios Clinics Langen, Paulinen Wiesbaden, 63225 Langen, Germany.
: Sirolimus-coated balloons (SCBs) have emerged as a promising alternative to paclitaxel-coated devices for the treatment of femoropopliteal lesions. However, real-world data on SCB performance in also complex peripheral arterial disease remains unknown. We sought to evaluate the safety and 12-month clinical outcomes of the Selution SLR™ balloon angioplasty in a challenging real-world patient cohort.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Cardiology, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China.
In this research, we explored the relationship between the AIP and clinical outcomes in patients undergoing PCI. A total of 2533 consecutive patients who underwent PCI were included in this retrospective cohort study, and the data from 2098 patients were used. AIP is calculated based on the log (triglycerides/high-density lipoprotein-cholesterol).
View Article and Find Full Text PDFAnn Vasc Surg
January 2025
Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
Objectives: Prediction of in-stent restenosis (ISR) is clinically important for patients with peripheral artery disease in their superficial femoral arteries (SFA) who have been treated with stenting. The aim of this study was to construct and validate a predictive model for ISR after SFA stenting based on a series of clinical and ultrasonic parameters.
Methods: This retrospective study included 381 patients who were treated with self-expanding bare nitinol stents in their SFA at our hospital between January 1, 2018, and January 1, 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!